{"id":55667,"date":"2023-04-11T13:04:09","date_gmt":"2023-04-11T11:04:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/"},"modified":"2023-04-11T13:04:09","modified_gmt":"2023-04-11T11:04:09","slug":"antibe-provides-april-2023-corporate-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/","title":{"rendered":"Antibe Provides April 2023 Corporate Update"},"content":{"rendered":"
\n

TORONTO–(BUSINESS WIRE)–$ATBPF<\/a>–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update.<\/p>\n

<\/a><\/p>\n

\nCRO Selected for PK\/PD Study for Otenaproxesul\u2019s New Formulation<\/b><\/p>\n

\nFurther to Antibe\u2019s update of February 15, 2023, the Company has now selected a clinical research organization (\u201cCRO\u201d) to carry out the pharmacokinetic\/pharmacodynamic (\u201cPK\/PD\u201d) study for otenaproxesul\u2019s new formulation. The purpose of the PK\/PD study is to confirm the optimal dosing regimens for the Phase II bunionectomy trial, slated to initiate in calendar Q4 2023 as previously announced.<\/p>\n

\nDILIsym Modeling for Otenaproxesul Expands to Chronic Pain Treatment Regimens<\/b><\/p>\n

\nWith the positive results attained in modeling otenaproxesul\u2019s liver safety in acute pain treatment regimens, the Company has now embarked on a DILIsym program to explore potential chronic treatment regimens. While this initiative is preliminary, the learning already achieved with DILIsym in combination with the positive animal results for otenaproxesul\u2019s new formulation provide the basis for this investigation. DILIsym is a sophisticated software model widely used to predict liver safety.<\/p>\n

\nStrategic Positioning Assessment for Otenaproxesul Completed<\/b><\/p>\n

\nAntibe has concluded a comprehensive strategic positioning assessment of otenaproxesul for acute pain in the U.S. market. The assessment identified a compelling commercial strategy and validated the drug\u2019s best-in-class positioning in a market with few novel therapies in development. In addition, new opportunities for competitive differentiation were identified and are being pursued. The assessment was conducted by a leading life science-focused marketing and commercialization agency.<\/p>\n

\nContinued Progress in Emerging Discovery Program<\/b><\/p>\n

\nAs noted in its February update, the Company has selected lead and back-up candidates for its inflammatory bowel disease (\u201cIBD\u201d) program. These candidates are being evaluated in animal efficacy models with a patent application filing expected in the current quarter. Separately, Antibe is investigating a family of anti-inflammatory compounds that recently demonstrated promising results in an initial animal model; the Company expects to be in a position to make a more comprehensive announcement in the upcoming quarter.<\/p>\n

\nNuance Pharma Dispute Proceeds to Arbitration<\/b><\/p>\n

\nFurther to the disclosure provided in the Company\u2019s most recent Annual Information Form (\u201cAIF\u201d), the dispute with Nuance Pharma has not yet been settled.1<\/sup> Accordingly, the parties will be commencing arbitration proceedings in early May under the rules of the Singapore International Arbitration Centre. The Company continues to consider Nuance\u2019s claims to be without merit and will provide updates concerning significant developments as they occur.<\/p>\n

\nAbout Antibe Therapeutics Inc.<\/b><\/p>\n

\nAntibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company\u2019s current pipeline includes assets that seek to overcome the gastrointestinal (\u201cGI\u201d) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (\u201cNSAIDs\u201d). Antibe\u2019s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today\u2019s NSAIDs for acute pain. Antibe\u2019s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company\u2019s next target is inflammatory bowel disease (\u201cIBD\u201d), a condition long in need of safer, more effective therapies. Learn more at antibethera.com<\/a>.<\/p>\n

\nForward Looking Information<\/b><\/p>\n

\nThis news release includes certain forward-looking statements under applicable securities laws, which may include, but are not limited to, the anticipated scope, timing, duration and completion of certain of the Company\u2019s clinical trial programs and studies and the anticipated timing for seeking market approval for certain of the Company\u2019s drugs and therapies for certain additional indications. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \u201cwill\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cpropose\u201d and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company\u2019s inability to timely execute on its business strategy and timely and successfully complete its clinical trials and studies, the Company\u2019s inability to obtain the necessary regulatory approvals related to its activities, risks associated with drug development generally and those risk factors set forth in the Company\u2019s public filings made in Canada and available on sedar.com. The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.<\/p>\n

\n_____________________________
\n
1<\/sup> See page 38 of Antibe\u2019s fiscal 2022 AIF on SEDAR or at antibethera.com\/wp-content\/uploads\/2022\/07\/ATE-2022-Annual-Information-Form.pdf<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nAntibe Therapeutics Inc.
\n
Christina Cameron
\n
VP Investor Relations
\n
+1 416-577-1443
\n
christina@antibethera.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK\/PD Study for Otenaproxesul\u2019s New Formulation Further to Antibe\u2019s update of February 15, 2023, the Company has now selected a clinical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55667","6":"format-standard","7":"category-industry"},"yoast_head":"\nAntibe Provides April 2023 Corporate Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibe Provides April 2023 Corporate Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK\/PD Study for Otenaproxesul\u2019s New Formulation Further to Antibe\u2019s update of February 15, 2023, the Company has now selected a clinical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T11:04:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Antibe Provides April 2023 Corporate Update\",\"datePublished\":\"2023-04-11T11:04:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/\"},\"wordCount\":809,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005462\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/\",\"name\":\"Antibe Provides April 2023 Corporate Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005462\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"datePublished\":\"2023-04-11T11:04:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005462\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005462\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-provides-april-2023-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibe Provides April 2023 Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibe Provides April 2023 Corporate Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Antibe Provides April 2023 Corporate Update - Pharma Trend","og_description":"TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK\/PD Study for Otenaproxesul\u2019s New Formulation Further to Antibe\u2019s update of February 15, 2023, the Company has now selected a clinical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-11T11:04:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Antibe Provides April 2023 Corporate Update","datePublished":"2023-04-11T11:04:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/"},"wordCount":809,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/","url":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/","name":"Antibe Provides April 2023 Corporate Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","datePublished":"2023-04-11T11:04:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230411005462\/en\/718346\/21\/ANTIBE-logo-RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/antibe-provides-april-2023-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Antibe Provides April 2023 Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55667"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55667\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}